Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News :

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors 
The feature you requested does not exist. However, we suggest the following feature:

Pfizer : Australian watchdog appeals to high court on Pfizer's alleged abuse of market power

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2018 | 07:43am CEST
A logo of Pfizer is displayed on a monitor outside of the New York Stock Exchange shortly after the opening bell in New York

MELBOURNE (Reuters) - Australia's competition watchdog said on Monday it would appeal to the nation's high court for a ruling on whether Pfizer Inc used its market power to limit competition for its cholesterol-lowering drug Lipitor.

The Australian Competition and Consumer Commission (ACCC) lost an appeal in May in a case alleging that Pfizer had abused its market power by offering big discounts and rebates on Lipitor to pharmacies, which bought large quantities of the drug and agreed to limit re-supply of competing generic atorvastatin products.

The commission said while the full Federal Court last month found that Pfizer had taken advantage of its market power, the court rejected the commission's view that Pfizer had done so in order to lessen competition.

So the ACCC has decided to appeal to the High Court of Australia.

"The ACCC is seeking clarity from the High Court on how to assess anti-competitive purpose, an important issue raised by this case," ACCC Commissioner Sarah Court said in statement.

The drug Lipitor generated annual sales of more than A$700 million (392.16 million pounds) for Pfizer in Australia before the company's patent expired there in May 2012, the commission said, when it launched the case against Pfizer in 2014.

Pfizer's spokesman in Sydney was not immediately available for comment on the commission's move to appeal to the High Court.

(Reporting by Sonali Paul, Editing by Sherry Jacob-Phillips)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
07:43aPFIZER : Australian watchdog appeals to high court on Pfizer's alleged abuse of market power
RE
07:43aAEON : Japan retail giant Aeon ramping up product sourcing from Vietnam
AQ
07:43aNMMA NATIONAL MARINE MANUFACTURERS ASSOCIATION : Discover Boating Taps Bloggers & Influencers to Inspire More People to Go Boating
PU
07:35aAustralia's Turnbull faces setback after lawmakers take aim at corporate tax cuts
RE
07:35aASMALLWORLD AG (SWX : ASWN): Hauck & Aufhäuser Privatbankiers initiates coverage of ASMALLWORLD with a 'Buy' rating and a target price of CHF 12.00 and CHF 20.00, respectively
EQ
07:35aGXP GERMAN PROPERTIES AG : GxP German Properties Completes Two Lettings in Erfurt
EQ
07:35aKLAIPEDOS NAFTA : Selection of candidates for independent Board members of AB Klaipėdos Nafta is announced
AQ
07:35aNORDEX : awarded contract in Brazil
EQ
07:32aShelf Drilling, Ltd. - Stabilization and Over-Allotment Option Notice
AQ
07:31aTELIASONERA : Share buy-backs in Telia Company during week 25, 2018
AQ
Latest news
Advertisement